Skip to main content

Table 1 Main input parameters of CEA model

From: Sarcopenia screening strategies in older people: a cost effectiveness analysis in Iran

Statistic variable Base case SD/(CI) Distribution Source
Sarcopenia prevalence in Iran 0.245 ±0.08 Beta [24]
Annual discount rate 0.05 (0.03–0.12) Beta  
Time Horizon (years) 25    
Sensitivity of screening tests
 EWGSOP 1 Beta [32] and Table S1
 SarSA-Mod 0.806 (0.767–0.842) Beta [32] and Table S1
 MSRA 0.804 ±0.08 Beta [31]
 SARC-F 0.168 (0.135–0.206) Beta [32] and Table S1
Specificity of screening tests
 EWGSOP 0.84 (0.816–0.862) Beta [32] and Table S1
 SarSA-Mod 0.788 (0.75–0.803) Beta [32] and Table S1
 MSRA 0.604 (0.543–0.664) Beta [31]
 SARC-F 0.866 (0.843–0.886) Beta [32] and Table S1
Probability of transition
 Probability of death in non-sarcopenic individuals (Normal Pop 60 yrs) 0.09   Beta IRI Life Table
 Probability of death in sarcopenic individuals 0.132 ±0.013 Beta [37, 38]
 Probability of death in sarcopenic individuals with cardiovascular disease 0.198 ±0.03 Beta [37, 38] And Calibration
 Probability of death for sarcopenic individuals with fracture 0.171 ±0.02 Beta [37, 38] And Experts opinion
 Probability of falling in sarcopenic individuals 0.273 ±0.03 Beta [39,40,41]
 Probability of fracture in sarcopenic individuals 0.40 ±0.05 Beta [37]
 Probability of cardiovascular disease (CVDs) in sarcopenic individuals 0.27 ±0.03 Beta [12] And Experts opinion
Costs($)
 Annual average cost of treatment interventions (vitamin D, Supplements, exercise, diet) 1119.048 ±119.047 Gamma Survey and Calibration
 Cost of usual gait speed test 0.714   Gamma Survey and Calibration
 Cost of handgrip strength test 1.309   Gamma Survey and Calibration
 Cost of DXA 42.857   Gamma Survey and Calibration
 Cost of MSRA 0.714   Gamma Survey and Calibration
 Cost of SARC-F 0.714   Gamma Survey and Calibration
 Cost of SARC-F (high-risk individuals) 44.880   Gamma Survey and Calibration
 Cost of SarSA-mod 1.785   Gamma Survey and Calibration
 EWGSOP (stage 1) 2.023   Gamma Survey and Calibration
 EWGSOP (stage 2) 42.857   Gamma Survey and Calibration
 Cost of treatment and care of fractures 3599.048 ±695.074 Gamma Survey and Calibration
 The initial average per capita cost of treatment and care of cardiovascular patients 4149.286   Gamma Survey and Calibration
 The incremental average per capita cost of treatment and care of cardiovascular patients 1904.762 ±190.476 Gamma Survey and Calibration
Utilities
 Non-sarcopenic individuals (Normal Pop > 60 yrs) 0.76   Beta [42, 43]
 Sarcopenic individuals 0.68   Beta [44]
 Sarcopenic individuals with fracture 0.51   Beta [40, 44, 45]
 Sarcopenic individuals with cardiovascular disease 0.56   Beta [44, 46]
 Sarcopenic individuals with cardiovascular disease and fracture 0.42   Beta [44,45,46,47]
Efficacy of interventions
 Efficacy of sarcopenia interventions (vitamin D, Supplements, exercise, diet) 40% ±15% Beta [48,49,50]